Erratum: A novel humanized mouse lacking murine p450 oxidoreductase for studying human drug metabolism (Nature Communications (2017) 8 (39) DOI: 10.1038/s41467-017-00049-x);A novel humanized mouse lacking murine P450 oxidoreductase for studying human drug metabolism

Nature Communications

Volumn 8, Issue 1, 2017, Pages

  Barzi, Mercedes ^a   Pankowicz, Francis P ^a,b   Zorman, Barry ^b   Liu, Xing ^b   Legras, Xavier ^a   Yang, Diane ^a,b   Borowiak, Malgorzata ^a,b,c   Bissig Choisat, Beatrice ^a,b   Sumazin, Pavel ^b   Li, Feng ^b   Bissig, Karl Dimiter ^a,b  

^a CENTER FOR CELL AND GENE THERAPY   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c McNair Medical Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATAZANAVIR; CYTOCHROME P450 REDUCTASE; GEFITINIB; ANTINEOPLASTIC AGENT; CYTOCHROME; CYTOCHROME P450; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; QUINAZOLINE DERIVATIVE;

CANCER; CELLS AND CELL COMPONENTS; CYTOCHROME; DRUG; DRUG DEVELOPMENT; ENZYME ACTIVITY; EXPERIMENTAL STUDY; HOMINID; METABOLISM; METABOLITE; MUTATION; RODENT; XENOBIOTICS;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG DEVELOPMENT; DRUG METABOLISM; GENE SILENCING; IMMUNOHISTOCHEMISTRY; LIVER CELL; LIVER MICROSOME; MOUSE; MOUSE STRAIN; NONHUMAN; PREDICTIVE VALUE; WESTERN BLOTTING; XENOBIOTIC METABOLISM; ANIMAL; CHIMERA; ENZYMOLOGY; FEMALE; GENETICS; GENOTYPE; HUMAN; INBRED MOUSE STRAIN; LIVER; MALE; METABOLISM;

ANIMALIA; MURINAE; MUS;

ANIMALS; ANTINEOPLASTIC AGENTS; ATAZANAVIR SULFATE; CHIMERA; CYTOCHROME P-450 ENZYME SYSTEM; CYTOCHROMES; FEMALE; GENOTYPE; HIV PROTEASE INHIBITORS; HUMANS; LIVER; MALE; MICE; MICE, INBRED STRAINS; QUINAZOLINES;

EID: 85020274354     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/s41467-017-01314-9     Document Type: Erratum

References (54)

1. Olson, H. et al. Concordance of the toxicity of pharmaceuticals in humans and in animals. Regul. Toxicol. Pharmacol. 32, 56-67 (2000).
2. Nelson, D. R. et al. Comparison of cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, pseudogenes and alternative-splice variants. Pharmacogenetics 14, 1-18 (2004).
3. Guengerich, F. P. & Cheng, Q. Orphans in the human cytochrome P450 superfamily: approaches to discovering functions and relevance in pharmacology. Pharmacol. Rev. 63, 684-699 (2011).
4. Mercer, D. F. et al. Hepatitis C virus replication in mice with chimeric human livers. Nat. Med. 7, 927-933 (2001).
5. Bissig, K. D., Le, T. T., Woods, N. B. & Verma, I. M. Repopulation of adult and neonatal mice with human hepatocytes: a chimeric animal model. Proc. Natl Acad. Sci. USA 104, 20507-20511 (2007).
6. Dandri, M. et al. Repopulation of mouse liver with human hepatocytes and in vivo infection with hepatitis B virus. Hepatology 33, 981-988 (2001).
7. -/- mice. Nat. Biotechnol. 25, 903-910 (2007).
8. Hasegawa, M. et al. The reconstituted 'humanized liver' in TK-NOG mice is mature and functional. Biochem. Biophys. Res. Commun. 405, 405-410 (2011).
9. Washburn, M. L. et al. A humanized mouse model to study hepatitis C virus infection, immune response, and liver disease. Gastroenterology 140, 1334-1344 (2011).
10. null mice. Biochem. Biophys. Res. Commun. 377, 248-252 (2008).
11. Heckel, J. L., Sandgren, E. P., Degen, J. L., Palmiter, R. D. & Brinster, R. L. Neonatal bleeding in transgenic mice expressing urokinase-type plasminogen activator. Cell 62, 447-456 (1990).
12. Tateno, C. et al. Near completely humanized liver in mice shows human-type metabolic responses to drugs. Am. J. Pathol. 165, 901-912 (2004).
13. Samuelsson, K. et al. Troglitazone metabolism and transporter effects in chimeric mice: a comparison between chimeric humanized and chimeric murinized FRG mice. Xenobiotica 44, 186-195 (2014).
14. Lootens, L. et al. Steroid metabolism in chimeric mice with humanized liver. Drug Test Anal. 1, 531-537 (2009).
15. Foster, J. R. et al. Differential effect of troglitazone on the human bile acid transporters, MRP2 and BSEP, in the PXB hepatic chimeric mouse. Toxicol. Pathol. 40, 1106-1116 (2012).
16. Xu, D. et al. Fialuridine induces acute liver failure in chimeric TK-NOG mice: a model for detecting hepatic drug toxicity prior to human testing. PLoS Med. 11, e1001628 (2014).
17. Bateman, T. J., Reddy, V. G., Kakuni, M., Morikawa, Y. & Kumar, S. Application of chimeric mice with humanized liver for study of human-specific drug metabolism. Drug Metab. Dispos. 42, 1055-1065 (2014).
18. Nishimura, T. et al. Using chimeric mice with humanized livers to predict human drug metabolism and a drug-drug interaction. J. Pharmacol. Exp. Ther. 344, 388-396 (2013).
19. Tanoue, C. et al. Prediction of human metabolism of the sedative-hypnotic zaleplon using chimeric mice transplanted with human hepatocytes. Xenobiotica 43, 956-962 (2013).
20. Bissig, K. D. et al. Human liver chimeric mice provide a model for hepatitis B and C virus infection and treatment. J. Clin. Invest. 120, 924-930 (2010).
21. Meuleman, P. et al. Morphological and biochemical characterization of a human liver in a uPA-SCID mouse chimera. Hepatology 41, 847-856 (2005).
22. Kato, K. et al. Development of murine Cyp3a knockout chimeric mice with humanized liver. Drug Metab. Dispos. 43, 1208-1217 (2015).
23. Nakada N. et al. Murine Cyp3a knockout chimeric mice with humanized liver: prediction of the metabolic profile of nefazodone in humans. Biopharm. Drug Dispos. 37, 3-14 (2016).
24. Shen, A. L., O'Leary, K. A. & Kasper, C. B. Association of multiple developmental defects and embryonic lethality with loss of microsomal NADPH-cytochrome P450 oxidoreductase. J. Biol. Chem. 277, 6536-6541 (2002).
25. Wu, L. et al. Conditional knockout of the mouse NADPH-cytochrome p450 reductase gene. Genesis 36, 177-181 (2003).
26. Henderson, C. J. et al. Inactivation of the hepatic cytochrome P450 system by conditional deletion of hepatic cytochrome P450 reductase. J. Biol. Chem. 278, 13480-13486 (2003).
27. Gu, J. et al. Liver-specific deletion of the NADPH-cytochrome P450 reductase gene: impact on plasma cholesterol homeostasis and the function and regulation of microsomal cytochrome P450 and heme oxygenase. J. Biol. Chem. 278, 25895-25901 (2003).
28. Thomas, K. R. & Capecchi, M. R. Site-directed mutagenesis by gene targeting in mouse embryo-derived stem cells. Cell 51, 503-512 (1987).
29. Skarnes, W. C. et al. A conditional knockout resource for the genome-wide study of mouse gene function. Nature 474, 337-342 (2011).
30. Farley, F. W., Soriano, P., Steffen, L. S. & Dymecki, S. M. Widespread recombinase expression using FLPeR (flipper) mice. Genesis 28, 106-110 (2000).
31. Haft, D. H., Selengut, J., Mongodin, E. F. & Nelson, K. E. A guild of 45 CRISPRassociated (Cas) protein families and multiple CRISPR/Cas subtypes exist in prokaryotic genomes. PLoS Comput. Biol. 1, e60 (2005).
32. Jinek, M. et al. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 337, 816-821 (2012).
33. Jansen, R., Embden, J. D., Gaastra, W. & Schouls, L. M. Identification of genes that are associated with DNA repeats in prokaryotes. Mol. Microbiol. 43, 1565-1575 (2002).
34. Bissig-Choisat, B. et al. Development and rescue of human familial hypercholesterolaemia in a xenograft mouse model. Nat. Commun. 6, 7339 (2015).
35. Weng, Y., DiRusso, C. C., Reilly, A. A., Black, P. N. & Ding, X. Hepatic gene expression changes in mouse models with liver-specific deletion or global suppression of the NADPH-cytochrome P450 reductase gene. Mechanistic implications for the regulation of microsomal cytochrome P450 and the fatty liver phenotype. J. Biol. Chem. 280, 31686-31698 (2005).
36. Williams, J. A. et al. Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab. Dispos. 32, 1201-1208 (2004).
37. Barker, A. J. et al. Studies leading to the identification of ZD1839 (IRESSA): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer. Bioorg. Med. Chem. Lett. 11, 1911-1914 (2001).
38. Herbst, R. S., Fukuoka, M. & Baselga, J. Gefitinib-a novel targeted approach to treating cancer. Nat. Rev. Cancer 4, 956-965 (2004).
39. Liu, X. et al. Metabolomics reveals the formation of aldehydes and iminium in gefitinib metabolism. Biochem. Pharmacol. 97, 111-121 (2015).
40. McKillop, D. et al. Metabolic disposition of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, in rat, dog and man. Xenobiotica 34, 917-934 (2004).
41. Scheffler, M., Di Gion, P., Doroshyenko, O., Wolf, J. & Fuhr, U. Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on 4-anilinoquinazolines. Clin. Pharmacokinet. 50, 371-403 (2011).
42. Li, F., Lu, J., Wang, L. & Ma, X. CYP3A-mediated generation of aldehyde and hydrazine in atazanavir metabolism. Drug Metab. Dispos. 39, 394-401 (2011).
43. Baillie, T. A. Future of toxicology-metabolic activation and drug design: challenges and opportunities in chemical toxicology. Chem. Res. Toxicol. 19, 889-893 (2006).
44. Guengerich, F. P. & MacDonald, J. S. Applying mechanisms of chemical toxicity to predict drug safety. Chem. Res. Toxicol. 20, 344-369 (2007).
45. Dalvie, D. et al. Assessment of three human in vitro systems in the generation of major human excretory and circulating metabolites. Chem. Res. Toxicol. 22, 357-368 (2009).
46. Anderson, S., Luffer-Atlas, D. & Knadler, M. P. Predicting circulating human metabolites: how good are we? Chem. Res. Toxicol. 22, 243-256 (2009).
47. Pettitt, S. J. et al. Agouti C57BL/6N embryonic stem cells for mouse genetic resources. Nat. Methods 6, 493-495 (2009).
48. Cradick, T. J., Qiu, P., Lee, C. M., Fine, E. J. & Bao, G. COSMID: a web-based tool for identifying and validating CRISPR/Cas off-target sites. Mol. Ther. Nucleic Acids 3, e214 (2014).
49. Hwang, W. Y. et al. Efficient genome editing in zebrafish using a CRISPR-Cas system. Nat. Biotechnol. 31, 227-229 (2013).
50. Cong, L. et al. Multiplex genome engineering using CRISPR/Cas systems. Science 339, 819-823 (2013).
51. Ponder, K. P. et al. Mouse hepatocytes migrate to liver parenchyma and function indefinitely after intrasplenic transplantation. Proc. Natl Acad. Sci. USA 88, 1217-1221 (1991).
52. Li, B. & Dewey, C. N. RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. BMC. Bioinformatics 12, 323 (2011).
53. Langmead, B. & Salzberg, S. L. Fast gapped-read alignment with Bowtie 2. Nat. Methods 9, 357-359 (2012).
54. Eisenberg, E. & Levanon, E. Y. Human housekeeping genes, revisited. Trends Genet. 29, 569-574 (2013).